Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

10 sept. 2025 10h00 HE | Source: NanoNewron

NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimer’s Disease Program

NanoNewron awarded a $2.5 million NIH grant to develop TNF-α inhibitors engineered to cross the Blood-Brain Barrier to treat Alzheimer’s disease
04 mars 2025 15h13 HE | Source: NanoNewron

NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound

Marco Taglietti, MD is appointed CEO of NanoNewron, a company developing TNF-α inhibitors for Alzheimer’s, engineered to cross the Blood-Brain Barrier
20 févr. 2025 12h30 HE | Source: NanoNewron

NanoNewron and its Research to Advance the Treatment of Alzheimer’s Disease are Featured by Rutgers University Newsletters and on Rutgers Today

NanoNewron, a biotech company developing biologics crossing the blood-brain barrier to treat Alzheimer’s, was featured by Rutgers University Newsletters